Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6991167 | 0.88 | PIN1 (0.52) | AOC3PIN1NPC1MEN1KMT2A | |
| SCHEMBL6987408 | 0.86 | MLYCD (0.51) | MLYCD | |
| SCHEMBL6989696 | 0.80 | NPC1 (0.55) | NPC1MEN1KMT2AKDM4E | |
| SCHEMBL6990995 | 0.76 | KMT2A (0.54) | PIN1MEN1KMT2A | |
| SCHEMBL6989375 | 0.75 | KMT2A (0.50) | NPC1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL8242118 | 0.72 | MEN1 (0.57) | TAAR1AOC3MEN1KMT2AHPGD | |
| SCHEMBL6989399 | 0.71 | ALDH1A1 (0.40) | KMT2AKDM4EMAPT | |
| SCHEMBL6989665 | 0.69 | NPC1 (0.40) | NPC1MAPT | |
| SCHEMBL19616099 | 0.68 | L3MBTL1 (0.51) | TAAR1AOC3MEN1KMT2AMLYCD | |
| SCHEMBL3056908 | 0.67 | TAAR1 (1.00) | TAAR1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | TAAR1 4179/4885AOC3 4668/4885PIN1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.